Mark J. Ratain to CD4-CD8 Ratio
This is a "connection" page, showing publications Mark J. Ratain has written about CD4-CD8 Ratio.
Connection Strength
0.008
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.008